Slingshot members are tracking this event:

Portola Pharmaceuticals Announces Dosing of First Patient in Phase 2a Study of Cerdulatinib for Treatment of Hematologic Cancer and Upcoming Presentations of New Phase 1 Clinical Data at ASCO and EHA Annual Meetings

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
PTLA Community voting in process
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 01, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Cerdulatinib, Phase 2a Study, Eha Annual Meetings, Asco